Genprex Stock Today

GNPX Stock  USD 1.16  0.10  9.43%   

Performance

10 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Over 68

 
High
 
Low
Quite High
Genprex is trading at 1.16 as of the 14th of December 2024; that is 9.43 percent increase since the beginning of the trading day. The stock's open price was 1.06. Genprex has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 17th of June 2024 and ending today, the 14th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of March 2018
Category
Healthcare
Classification
Health Care
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Genprex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 8.51 M outstanding shares of which 433.11 K shares are currently shorted by private and institutional investors with about 0.02 trading days to cover. More on Genprex

Moving against Genprex Stock

  0.61MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.36LLY Eli LillyPairCorr
  0.31PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr

Genprex Stock Highlights

CEO, PresidentRyan MS
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities3.4 M3.3 M
Sufficiently Up
Slightly volatile
Total Assets15.4 M10.7 M
Way Up
Slightly volatile
Total Current Assets13.8 M7.5 M
Way Up
Slightly volatile
Debt Levels
Genprex can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genprex's financial leverage. It provides some insight into what part of Genprex's total assets is financed by creditors.
Liquidity
Genprex currently holds 3.25 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Genprex has a current ratio of 10.5, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Genprex's use of debt, we should always consider it together with its cash and equity.

Total Cash From Operating Activities

(23.5 Million)
Genprex (GNPX) is traded on NASDAQ Exchange in USA. It is located in 3300 Bee Cave Road, Austin, TX, United States, 78746 and employs 21 people. Genprex is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.87 M. Genprex conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.51 M outstanding shares of which 433.11 K shares are currently shorted by private and institutional investors with about 0.02 trading days to cover. Genprex currently holds about 25.52 M in cash with (24.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Genprex Probability Of Bankruptcy
Ownership Allocation
Genprex retains 6.4 (percent) of its outstanding shares held by insiders and 10.9 (percent) owned by outside corporations.
Check Genprex Ownership Details

Genprex Stock Institutional Holders

InstituionRecorded OnShares
Ashton Thomas Securities, Llc2024-09-30
127
Hanson Mcclain Inc2024-09-30
125
Group One Trading, Lp2024-09-30
114
Royal Bank Of Canada2024-09-30
63.0
Advisor Group Holdings, Inc.2024-09-30
58.0
Vitalstone Financial Llc2024-09-30
10.0
Global Retirement Partners, Llc.2024-09-30
5.0
Jpmorgan Chase & Co2024-09-30
5.0
Wells Fargo & Co2024-06-30
0.0
Ubs Group Ag2024-09-30
56.4 K
Two Sigma Securities, Llc2024-09-30
23 K
View Genprex Diagnostics

Genprex Historical Income Statement

At this time, Genprex's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 21.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.2 M in 2024. View More Fundamentals

Genprex Stock Against Markets

Genprex Corporate Management

CMA CPACo ControllerProfile
Kalyn DabbsSr MarketingProfile
Suzanne ThorntonJonesSenior QualityProfile
David SchlossSenior ResourcesProfile
William GannonMember AffairsProfile
Mark MDChief OfficerProfile

Additional Tools for Genprex Stock Analysis

When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.